Foghorn Therapeutics

CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the…

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the…

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the…

-   Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program -   Collaboration includes three additional discovery programs -   Foghorn to receive $300 million…

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the…

-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma -- Continue to enroll patients in phase 1…

CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the…

FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9 Foghorn’s first protein degrader program to enter the clinic; continues pre-clinical work on other protein degrader programs for broad range of cancers…

- First clinical candidate of a new class of therapeutics directly targeting the chromatin regulatory system - FHD-286 is a highly potent, selective, allosteric, oral, small molecule inhibitor of BRG1/BRM CAMBRIDGE, Mass., May 17, 2021…